Koyfin Home > Directory > Health Care > Alexion Pharm Inc > Long-Term Debt

Alexion Pharm Inc Long-Term Debt Chart (ALXN)

Alexion Pharm Inc annual/quarterly Long-Term Debt from 2010 to 2020.
  • Alexion Pharm Inc Long-Term Debt for the quarter ending September 09, 2020 was $2,511m a 3.74% increase of 94m year over year
  • Alexion Pharm Inc Long-Term Debt for the last 12 months ending September 09, 2020 was $2,511m a 3.74% increase of 94m year over year
  • Alexion Pharm Inc Annual Long-Term Debt for 2019 was $2,417m a -4.22% decrease of -102m from 2018
  • Alexion Pharm Inc Annual Long-Term Debt for 2018 was $2,519m a -8.01% decrease of -202m from 2017
  • Alexion Pharm Inc Annual Long-Term Debt for 2017 was $2,721m a -6.15% decrease of -167m from 2016
Other Cash Flow Metrics:
  • Alexion Pharm Inc Cash Flow from Operations for the quarter ending September 09, 2018 was $387m a 33.45% increase of 130m year over year
  • Alexion Pharm Inc Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $227m a 35.57% increase of 81m year over year
  • Alexion Pharm Inc Total Revenue for the quarter ending December 12, 2018 was $1,129m a 17.53% increase of 198m year over year
View Chart On Koyfin

Quarterly ALXN Long-Term Debt Data

09/2020$2,511m
06/2020$2,381m
03/2020$2,419m
12/2019$2,417m
09/2019$2,462m
06/2019$2,491m
03/2019$2,501m
12/2018$2,519m
09/2018$2,533m
06/2018$2,565m

Annual ALXN Long-Term Debt Data

2019$2,417m
2018$2,519m
2017$2,721m
2016$2,888m
2015$3,254m
2014$10m
2013$65m
2012$101m
2010$4m